Novartis

First gene therapy for cancer approved: What health execs should knowThe first therapy based on gene transfer has been approved by the FDA. What’s next for healthcare executives?
FDA Approves First Gene TherapyWhy the agency says the approval of Novartis’ new therapy is historic.
Targeting dry eye in glaucoma patients
Targeting dry eye in glaucoma patientsA poor ocular surface is a common condition in glaucoma patients due to the incidence of dry eye, age, and use of benzalkonium chloride (BAK). Poor compliance with glaucoma therapy can result. Use of point-of-care testing can help identify patients with a poor ocular surface and drive treatment decisions. Treatment options, including surgical, are discussed.
Novartis Alcon changes build better platform for ophthalmologyAlcon Laboratories pharmaceutical products have been moved into the Novartis Pharmaceutical Division. The switch means a sharper focus on research and development in ophthalmology as well as better access to Norvartis’ patient services and support capabilities.
New universal companion diagnostic paves the way for precision oncologyFDA approves new diagnostic test for non-small cell lung cancer.
Combination pack approved for breast cancer treatmentFDA approves ribociclib plus letrozole to treat a subset of advanced breast cancer patients.
Aflibercept rivals laser for diabetic retinopathyIntravitreal aflibercept worked better than panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) in a new head-to-head trial, according to researchers.
FDA approves first targeted leukemia drug for certain patients, plus 2 moreLate last week, FDA approved a new drug to treat acute myeloid leukemia (AML), the first treatment for Batten disease, and expanded the use of a current drug to treat liver cancer.
Preparing your patient for PRKPhotorefractive keratectomy (PRK) was the original excimer laser procedure approved by the FDA—and is still a safe and effective treatment of refractive errors. PRK has the benefits of no-flap creation; therefore, there is no risk of flap complications.
How to combat vernal keratoconjunctivitisIt is a precarious position considering the desire to find the perfect remedy— yet with vernal keratoconjunctivitis (VKC), there is no magic bullet.